Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial

Prasanna Jagannathan (), Jason R. Andrews, Hector Bonilla, Haley Hedlin, Karen B. Jacobson, Vidhya Balasubramanian, Natasha Purington, Savita Kamble, Christiaan R. Vries, Orlando Quintero, Kent Feng, Catherine Ley, Dean Winslow, Jennifer Newberry, Karlie Edwards, Colin Hislop, Ingrid Choong, Yvonne Maldonado, Jeffrey Glenn, Ami Bhatt, Catherine Blish, Taia Wang, Chaitan Khosla, Benjamin A. Pinsky, Manisha Desai, Julie Parsonnet and Upinder Singh ()
Additional contact information
Prasanna Jagannathan: Stanford University
Jason R. Andrews: Stanford University
Hector Bonilla: Stanford University
Haley Hedlin: Stanford University
Karen B. Jacobson: Stanford University
Vidhya Balasubramanian: Stanford University
Natasha Purington: Stanford University
Savita Kamble: Stanford University
Christiaan R. Vries: Stanford University
Orlando Quintero: Stanford University
Kent Feng: Stanford University
Catherine Ley: Stanford University
Dean Winslow: Stanford University
Jennifer Newberry: Stanford University
Karlie Edwards: Stanford University
Colin Hislop: Stanford University
Ingrid Choong: Stanford University
Yvonne Maldonado: Eiger BioPharmaceuticals
Jeffrey Glenn: Stanford University
Ami Bhatt: Stanford University
Catherine Blish: Stanford University
Taia Wang: Stanford University
Chaitan Khosla: Stanford University
Benjamin A. Pinsky: Stanford University
Manisha Desai: Stanford University
Julie Parsonnet: Stanford University
Upinder Singh: Stanford University

Nature Communications, 2021, vol. 12, issue 1, 1-10

Abstract: Abstract Type III interferons have been touted as promising therapeutics in outpatients with coronavirus disease 2019 (COVID-19). We conducted a randomized, single-blind, placebo-controlled trial (NCT04331899) in 120 outpatients with mild to moderate COVID-19 to determine whether a single, 180 mcg subcutaneous dose of Peginterferon Lambda-1a (Lambda) within 72 hours of diagnosis could shorten the duration of viral shedding (primary endpoint) or symptoms (secondary endpoint). In both the 60 patients receiving Lambda and 60 receiving placebo, the median time to cessation of viral shedding was 7 days (hazard ratio [HR] = 0.81; 95% confidence interval [CI] 0.56 to 1.19). Symptoms resolved in 8 and 9 days in Lambda and placebo, respectively, and symptom duration did not differ significantly between groups (HR 0.94; 95% CI 0.64 to 1.39). Both Lambda and placebo were well-tolerated, though liver transaminase elevations were more common in the Lambda vs. placebo arm (15/60 vs 5/60; p = 0.027). In this study, a single dose of subcutaneous Peginterferon Lambda-1a neither shortened the duration of SARS-CoV-2 viral shedding nor improved symptoms in outpatients with uncomplicated COVID-19.

Date: 2021
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-021-22177-1 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-22177-1

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-021-22177-1

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().